Drugmakers and the US FDA produced another tsunami of drug development news last week, and some of it was too big to fit into this edition. So don't miss our coverage of two breakthrough therapy designations being rescinded (see sidebar), as well as a Genentech Inc. supplemental new drug application (sNDA) submission under the Real-Time Oncology Review (RTOR) pilot program (more on that in a subsequent issue of the Pink Sheet).
Here's the rest of your news
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?